These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

624 related articles for article (PubMed ID: 19721065)

  • 1. Diversity, epidemiology, and genetics of class D beta-lactamases.
    Poirel L; Naas T; Nordmann P
    Antimicrob Agents Chemother; 2010 Jan; 54(1):24-38. PubMed ID: 19721065
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genetics of extended-spectrum beta-lactamases.
    Jacoby GA
    Eur J Clin Microbiol Infect Dis; 1994; 13 Suppl 1():S2-11. PubMed ID: 7821301
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Carbapenemases: molecular diversity and clinical consequences.
    Poirel L; Pitout JD; Nordmann P
    Future Microbiol; 2007 Oct; 2(5):501-12. PubMed ID: 17927473
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New beta-lactamases: a paradigm for the rapid response of bacterial evolution in the clinical setting.
    Rossolini GM; Docquier JD
    Future Microbiol; 2006 Oct; 1(3):295-308. PubMed ID: 17661642
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evolution and epidemiology of extended-spectrum beta-lactamases (ESBLs) and ESBL-producing microorganisms.
    Gniadkowski M
    Clin Microbiol Infect; 2001 Nov; 7(11):597-608. PubMed ID: 11737084
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Beta-lactamases and their role in resistance. PART 2: beta-lactamases in 21st century].
    Bedenić B
    Lijec Vjesn; 2005; 127(1-2):12-21. PubMed ID: 16145868
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization of VIM-2, a carbapenem-hydrolyzing metallo-beta-lactamase and its plasmid- and integron-borne gene from a Pseudomonas aeruginosa clinical isolate in France.
    Poirel L; Naas T; Nicolas D; Collet L; Bellais S; Cavallo JD; Nordmann P
    Antimicrob Agents Chemother; 2000 Apr; 44(4):891-7. PubMed ID: 10722487
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Acquired carbapenem-hydrolyzing beta-lactamases and their genetic support.
    Poirel L; Nordmann P
    Curr Pharm Biotechnol; 2002 Jun; 3(2):117-27. PubMed ID: 12022255
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epidemiological, Physiological, and Molecular Characteristics of a Brazilian Collection of Carbapenem-Resistant Acinetobacter baumannii and Pseudomonas aeruginosa.
    Dias VC; Resende JA; Bastos AN; De Andrade Bastos LQ; De Andrade Bastos VQ; Bastos RV; Diniz CG; Da Silva VL
    Microb Drug Resist; 2017 Oct; 23(7):852-863. PubMed ID: 28437232
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Appearance of extended-spectrum beta-lactamases].
    Iyobe S
    Nihon Rinsho; 1997 May; 55(5):1219-24. PubMed ID: 9155178
    [TBL] [Abstract][Full Text] [Related]  

  • 11. OXA-58, a novel class D {beta}-lactamase involved in resistance to carbapenems in Acinetobacter baumannii.
    Poirel L; Marqué S; Héritier C; Segonds C; Chabanon G; Nordmann P
    Antimicrob Agents Chemother; 2005 Jan; 49(1):202-8. PubMed ID: 15616297
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Resistance to cephalosporins and carbapenems in Gram-negative bacterial pathogens.
    Pfeifer Y; Cullik A; Witte W
    Int J Med Microbiol; 2010 Aug; 300(6):371-9. PubMed ID: 20537585
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Acinetobacter baumannii: biology and drug resistance - role of carbapenemases.
    Nowak P; Paluchowska P
    Folia Histochem Cytobiol; 2016; 54(2):61-74. PubMed ID: 27270503
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Carbapenemases: the versatile beta-lactamases.
    Queenan AM; Bush K
    Clin Microbiol Rev; 2007 Jul; 20(3):440-58, table of contents. PubMed ID: 17630334
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epidemiology of β-Lactamase-Producing Pathogens.
    Bush K; Bradford PA
    Clin Microbiol Rev; 2020 Mar; 33(2):. PubMed ID: 32102899
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular basis of selective inhibition and slow reversibility of avibactam against class D carbapenemases: a structure-guided study of OXA-24 and OXA-48.
    Lahiri SD; Mangani S; Jahić H; Benvenuti M; Durand-Reville TF; De Luca F; Ehmann DE; Rossolini GM; Alm RA; Docquier JD
    ACS Chem Biol; 2015 Feb; 10(2):591-600. PubMed ID: 25406838
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Kinetics of Sulbactam Hydrolysis by β-Lactamases, and Kinetics of β-Lactamase Inhibition by Sulbactam.
    Shapiro AB
    Antimicrob Agents Chemother; 2017 Dec; 61(12):. PubMed ID: 28971872
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Class D β-lactamases do exist in Gram-positive bacteria.
    Toth M; Antunes NT; Stewart NK; Frase H; Bhattacharya M; Smith CA; Vakulenko SB
    Nat Chem Biol; 2016 Jan; 12(1):9-14. PubMed ID: 26551395
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel acquired metallo-beta-lactamase gene, bla(SIM-1), in a class 1 integron from Acinetobacter baumannii clinical isolates from Korea.
    Lee K; Yum JH; Yong D; Lee HM; Kim HD; Docquier JD; Rossolini GM; Chong Y
    Antimicrob Agents Chemother; 2005 Nov; 49(11):4485-91. PubMed ID: 16251286
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Analysis of a novel class 1 integron containing metallo-beta-lactamase gene VIM-2 in Pseudomonas aeruginosa.
    Jeong JH; Shin KS; Lee JW; Park EJ; Son SY
    J Microbiol; 2009 Dec; 47(6):753-9. PubMed ID: 20127470
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.